-
1.发明申请2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof 有权2,6-Dinitrogen-Containing替代嘌呤衍生物，其制备和用途公开(公告)号：US20100144663A1
公开(公告)日：2010-06-10
申请号：US12596669
申请日：2008-04-17
申请人： Zhanggui Wu , Weidong Ye , Jianyong Yuan , Gang Chen
发明人： Zhanggui Wu , Weidong Ye , Jianyong Yuan , Gang Chen
IPC分类号： A61K31/52 , C07D473/16 , C07H19/16 , A61K31/7076 , A61P35/00
CPC分类号： C07D473/16 , C07H19/16 , C07H19/173 , C07H19/20
摘要： The present invention provides 2,6-dinitrogen-containing substituted purine compounds of formula (A) or salts or solvates thereof or the solvates of salts thereof, as well as pharmaceutical compositions containing such compounds. The compounds of the present invention have the characteristics of lower toxicity, broad anticancer spectrum, higher anticancer activity, good stability and the like. The compounds are useful for the manufacture of an antitumor medicament. The present invention also provides a process for preparing these compounds.
摘要翻译： 本发明提供式（A）的2,6-二氮的取代嘌呤化合物或其盐或溶剂合物或其盐的溶剂化物，以及含有这些化合物的药物组合物。 本发明化合物具有毒性低，抗癌谱广，抗癌活性高，稳定性好等特点。 该化合物可用于制造抗肿瘤药物。 本发明还提供了制备这些化合物的方法。
-
2.发明授权Crystalline form of entecavir, its preparation and the pharmaceutical composition and uses thereof 有权恩替卡韦的结晶形式及其制备及其药物组合物及其用途公开(公告)号：US08937076B2
公开(公告)日：2015-01-20
申请号：US12527215
申请日：2008-01-31
申请人： Weidong Ye , Jianyong Yuan , Jingjing Nie , Duanjun Xu , Chaotian Chen
发明人： Weidong Ye , Jianyong Yuan , Jingjing Nie , Duanjun Xu , Chaotian Chen
IPC分类号： A61K31/522 , C07D473/18
CPC分类号： C07D473/18
摘要： The present invention relates to a crystalline form of entecavir and its process for preparation, and provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of entecavir. Furthermore, the present invention also provides a use of the crystalline form of entecavir in preparation for a medicament for the treatment of hepatitis B viral infections. The present invention is beneficial toe preparations for pharmaceutical formulations and enhancements of its bioavailability.
摘要翻译： 本发明涉及恩替卡韦的结晶形式及其制备方法，并且提供包含治疗有效量的恩替卡韦结晶形式的药物组合物。 此外，本发明还提供恩替卡韦的结晶形式用于制备用于治疗乙型肝炎病毒感染的药物的用途。 本发明有益于药物制剂的制备和其生物利用度的提高。
-
3.发明授权2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof 有权2,6-二氮杂的取代嘌呤衍生物，其制备和用途公开(公告)号：US08580763B2
公开(公告)日：2013-11-12
申请号：US12596669
申请日：2008-04-17
申请人： Zhanggui Wu , Weidong Ye , Jianyong Yuan , Gang Chen
发明人： Zhanggui Wu , Weidong Ye , Jianyong Yuan , Gang Chen
CPC分类号： C07D473/16 , C07H19/16 , C07H19/173 , C07H19/20
摘要： The present invention provides 2,6-dinitrogen-containing substituted purine compounds of formula (A) or salts or solvates thereof or the solvates of salts thereof, as well as pharmaceutical compositions containing such compounds. The compounds of the present invention have the characteristics of lower toxicity, broad anticancer spectrum, higher anticancer activity, good stability and the like. The compounds are useful for the manufacture of an antitumor medicament. The present invention also provides a process for preparing these compounds.
摘要翻译： 本发明提供式（A）的2,6-二氮的取代嘌呤化合物或其盐或溶剂合物或其盐的溶剂化物，以及含有这些化合物的药物组合物。 本发明化合物具有毒性低，抗癌谱广，抗癌活性高，稳定性好等特点。 该化合物可用于制造抗肿瘤药物。 本发明还提供了制备这些化合物的方法。
-
-
搜索结果
3 条记录 (耗时 0.012 秒)
